Alnylam (ALNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

Here is how Sensus Healthcare, Inc. (SRTS) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.

After about five years working behind the scenes, Arrakis Therapeutics is unveiling that its lead program will aim to treat ...

New therapy for Huntington’s disease ‘may slow progression’ - There are thought to be around 7,000 people living with ...

By collecting data from four different antenna orientations post-surgery, researchers are detecting significantly more detailed information on breast cancer than a traditional single-orientation scan ...

Dr. Waleed Hassanein, Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024, the TransMedics Investor & Analyst Day on December 10, 2024, ...

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

As part of the COVID-19 International Research Team, researchers at the Johns Hopkins Kimmel Cancer Center, Children’s Hospital of Philadelphia, the University of Pittsburgh and Weill Cornell Medicine ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

StockNews.com cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a buy rating to a hold rating in a ...